Related Articles
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women
Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma
Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models